Tempest Net Income from 2010 to 2025
| TPST Stock | USD 0.95 0.05 5.56% |
Net Loss | First Reported 2011-09-30 | Previous Quarter -9.6 M | Current Value -10.6 M | Quarterly Volatility 5.4 M |
Check Tempest Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tempest Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 416.2 K, Interest Expense of 1.7 M or Selling General Administrative of 15.4 M, as well as many indicators such as Price To Sales Ratio of 1.36, Dividend Yield of 0.0 or PTB Ratio of 3.14. Tempest financial statements analysis is a perfect complement when working with Tempest Therapeutics Valuation or Volatility modules.
Tempest | Net Income |
Latest Tempest Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Tempest Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Tempest Therapeutics financial statement analysis. It represents the amount of money remaining after all of Tempest Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Tempest Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tempest Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (29.49 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Tempest Net Income Regression Statistics
| Arithmetic Mean | (36,360,627) | |
| Geometric Mean | 31,575,840 | |
| Coefficient Of Variation | (55.10) | |
| Mean Deviation | 14,894,530 | |
| Median | (29,550,000) | |
| Standard Deviation | 20,035,064 | |
| Sample Variance | 401.4T | |
| Range | 68.8M | |
| R-Value | (0.10) | |
| Mean Square Error | 425.5T | |
| R-Squared | 0.01 | |
| Significance | 0.70 | |
| Slope | (433,837) | |
| Total Sum of Squares | 6021.1T |
Tempest Net Income History
Other Fundumenentals of Tempest Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Tempest Therapeutics Net Income component correlations
About Tempest Therapeutics Financial Statements
Tempest Therapeutics shareholders use historical fundamental indicators, such as Net Income, to determine how well the company is positioned to perform in the future. Although Tempest Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Tempest Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tempest Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -33.9 M | -35.6 M | |
| Net Loss | -25.5 M | -26.7 M | |
| Net Loss | -28 M | -29.4 M | |
| Net Loss | (1.72) | (1.81) | |
| Net Income Per E B T | 0.93 | 0.81 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.